BRIDGEBIO PHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.56 USD | +1.97% |
|
+5.81% | -24.70% |
Presentation Operator MessageOperator (Operator)Welcome to the 2020 Annual Meeting for BridgeB...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
Sector
Pharmaceuticals
Calendar
20/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
29.97
USD
Average target price
50.54
USD
Spread / Average Target
+68.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.70% | 5.61B | |
| +0.10% | 91.42B | |
| +2.76% | 41.08B | |
| -11.61% | 34.26B | |
| +53.68% | 25.27B | |
| -9.73% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +5.24% | 9.16B | |
| -6.90% | 8.22B |
- Stock Market
- Equities
- BBIO Stock
- News BridgeBio Pharma, Inc.
- Transcript : BridgeBio Pharma, Inc. - Shareholder/Analyst Call
